Nexpoint Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Nexpoint Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.4M	Buy	+1,602,557	New	+$47.3M	3.37%	13

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nexpoint Asset Management's CPRX Position: Q2 2026 in Review

Nexpoint Asset Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 1,602,557 shares worth $50.4M. The stake represents 3.37% of the portfolio and ranks #13 among its holdings.

395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Nexpoint Asset Management held 1,602,557 shares of Catalyst Pharmaceutical worth $50.4M as of Q2 2026.
Catalyst Pharmaceutical was a new Nexpoint Asset Management position in Q2 2026.
Catalyst Pharmaceutical made up 3.37% of Nexpoint Asset Management's portfolio in Q2 2026, its #13 holding.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Nexpoint Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.